What is AlphaVax?
AlphaVax Inc. is at the forefront of vaccine development, leveraging proprietary RNA particle technology for both human and veterinary applications. The company's focus spans anti-infective and anti-cancer vaccines, with a strong emphasis on cancer immunotherapy. AlphaVax has cultivated a robust pipeline of seven vaccine candidates targeting critical areas such as human cytomegalovirus, influenza A virus, prostate cancer, and HIV-1. Having successfully navigated multiple Phase 1 clinical trials, AlphaVax's innovative approach is designed to harness the immune system to identify and neutralize various cancers, showing encouraging outcomes in improving patient survival rates.
How much funding has AlphaVax raised?
AlphaVax has raised a total of $31.9M across 3 funding rounds:
Series B
$8.2M
Series C
$11M
Series E
$12.7M
Series B (2000): $8.2M, investors not publicly disclosed
Series C (2000): $11M, investors not publicly disclosed
Series E (2007): $12.7M, investors not publicly disclosed
What's next for AlphaVax?
With the recent major strategic investment, AlphaVax is poised to accelerate its clinical development programs and further validate its RNA particle technology. This funding is expected to fuel the progression of its vaccine candidates through advanced clinical trials, potentially bringing life-saving immunotherapies closer to market. The company's strategic focus on both infectious diseases and oncology positions it to address significant unmet medical needs, making it a key player in the biopharmaceutical landscape.
See full AlphaVax company page
